Samsrita Labs Limited approved material related party transactions with S Labs Hygiene Care Private Limited, involving a ₹1 crore investment and ₹25 crore in sales. The board also sanctioned an unsecured loan of up to ₹1 crore from a non-executive director.

The transactions were approved during the board meeting held on September 28, 2026. The investment in S Labs Hygiene Care is structured as Compulsory Convertible Preference Shares (CCPS). The proposed sale transactions are capped at an aggregate value of ₹25 crore. Both items require prior shareholder approval, valid for one year from the date of such approval.

Related party details and sector expansion

S Labs Hygiene Care Private Limited is a related party due to a common director, Ravikanth Naga Pattabhi Chopperla, who holds 80% of the equity share capital of the target entity. The company operates in the pet care industry, focusing on grooming, hygiene, and wellness products. Samsrita Labs recently expanded its main objects clause to include this segment, aiming for commercial synergies and business volume growth.

The target entity was incorporated on July 10, 2026. Consequently, financial information for FY26 and previous years is not applicable. The investment consideration is cash, with the exact issue price to be determined by regulatory valuation rules at execution. The acquisition timeline extends to June 30, 2027.

Director loan and meeting schedule

The board approved availing an unsecured loan of up to ₹1 crore towards working capital from Ravikanth Naga Pattabhi Chopperla, Non-Executive Director. This loan is also subject to prior shareholder approval. The first Extra-Ordinary General Meeting for FY27 is scheduled for October 26, 2026, via video conferencing.

What the numbers show

The aggregate exposure to S Labs Hygiene Care Private Limited through these approved transactions totals ₹26 crore (₹1 crore investment + ₹25 crore sales). Given that S Labs Hygiene Care was incorporated just over two months prior to the board meeting (July 10, 2026), the company has no historical turnover data. The proposed sales volume of ₹25 crore represents a significant immediate revenue commitment relative to the target's nascent stage, indicating a strategic pivot by Samsrita Labs into the pet care segment through this related party.

Samsrita Labs Limited reported a standalone loss of ₹31.47 lakh for the quarter ended June 30, 2026 (Q1FY27), widening from the ₹11.87 lakh loss recorded in the preceding quarter. The Hyderabad-based healthcare company generated no revenue from operations during the period, mirroring the nil revenue figure from Q4FY26.

The Board of Directors approved the unaudited standalone and consolidated financial results in a meeting held on August 13, 2026. The financial statements were prepared in accordance with Ind AS and reviewed by statutory auditors MGR & Co Chartered Accountants.

Financial Performance

The company’s total expenses for the quarter stood at ₹31.47 lakh, a significant increase from ₹16.83 lakh in the preceding quarter. This rise was primarily driven by a jump in other expenses, which climbed to ₹21.55 lakh from ₹7.32 lakh in Q4FY26. Employee benefit expenses also increased to ₹9.80 lakh from ₹7.83 lakh.

While revenue from operations remained at zero, the company recorded other income of ₹3.15 lakh, consistent with the previous quarter. Consequently, total revenue was limited to this other income component.

Consolidated Results

On a consolidated basis, Samsrita Labs reported a net loss of ₹18.87 lakh for the quarter, an improvement from the ₹48.16 lakh loss in the preceding quarter. This improvement was largely due to the share of profit from associate companies, which contributed ₹12.60 lakh, compared to a share of loss of ₹36.29 lakh in Q4FY26.

The consolidated entity includes two associate companies: Krisani Bio Sciences Private Limited and Qrops Advisory Services Private Limited. The group’s share of profit after tax from these associates helped offset the parent company’s operational losses.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the company’s reliance on its associate entities for current profitability. While the standalone unit incurred higher operating costs with no revenue generation, the equity pick-up from associates provided a critical buffer, reducing the consolidated loss by over 60% compared to the previous quarter. This structure suggests that near-term financial health is heavily dependent on the performance of Krisani Bio Sciences and Qrops Advisory Services rather than core standalone operations.